Polygenic risk scores used for Parkinson's Disease treatment and prognosis
Okolie, Brianna
Okolie, Brianna
Citations
Altmetric:
License
License
DOI
Abstract
Parkinson’s disease is the second most common neurodegenerative disorder, characterized by progressive degeneration of dopamine-producing neurons in the brain. While genetic factors contribute to disease risk, genetic testing is not routinely offered in clinical settings, limiting its potential to inform prognosis, and treatment response. This infographic addresses the gap in clinical application of genetic testing by highlighting the role of polygenic risk scores (PRS) as predictive tools. PRS aggregate the effects of genetic variants to improve risk assessment and clinical decision-making. Advancing research and drug development, PRS have the potential to enhance public health strategies and improve patient outcomes.
Description
Undergraduate
Date
2025-05-29